Antidiabetics Market Forecast

Datamonitor, September 2010

The antidiabetics market is expected to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of Actos, with franchise sales reaching nearly $6 billion by 2019. Pipeline candidates will make up 30% of sales in 2019, with once-weekly GLP-1 agonists and new long-acting insulin analogs meeting success.

Reasons to Purchase

- Quantify the future size of the antidiabetics market from 2010-2019 and identify opportunities for new products
- Examine the future performance of leading antidiabetic brands and the growth of generics and insulin biosimilars
- Understand the barriers to uptake for novel antidiabetic agents

Customers who bought this item also bought

• Forecast Insight: Antidiabetics - Diabetes Market Growth Driven by Epidemiological Trends and Rich Pipeline
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
• Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.
• R&D Trends: Insulin Antidiabetics - The Future is Analogs
• Type 2 Diabetes (Event Driven)
• France Diabetes Market Forecast 2011-2016
• U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010
• Italy Diabetes Market Forecast 2011-2016
• Japan Diabetes Market Report & Forecast 2011-2016